Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Medical Informatics

Date Submitted: Apr 4, 2024
Date Accepted: Jun 8, 2024

The final, peer-reviewed published version of this preprint can be found here:

Integrating Clinical Data and Medical Imaging in Lung Cancer: Feasibility Study Using the Observational Medical Outcomes Partnership Common Data Model Extension

Yoo S, Ji H, Kim S, Sunwoo L, Jang S, Lee HY

Integrating Clinical Data and Medical Imaging in Lung Cancer: Feasibility Study Using the Observational Medical Outcomes Partnership Common Data Model Extension

JMIR Med Inform 2024;12:e59187

DOI: 10.2196/59187

PMID: 38996330

PMCID: 11282389

Integrating Clinical Data and Medical Imaging in Lung Cancer: A Feasibility Study Using the OMOP Common Data Model Extension

  • Sooyoung Yoo; 
  • Hyerim Ji; 
  • Seok Kim; 
  • Leonard Sunwoo; 
  • Sowon Jang; 
  • Ho-Young Lee

ABSTRACT

Background:

Digital transformation, particularly the integration of medical imaging with clinical data, is vital in personalized medicine. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) standardizes health data. However, integrating medical imaging remains a challenge.

Objective:

This study proposes a method for combining medical imaging data with the OMOP CDM to improve multimodal research.

Methods:

Our approach included the analysis and selection of Digital Imaging and Communications in Medicine (DICOM) header tags, validation of data formats, and alignment according to the OMOP CDM framework. The FHIR ImagingStudy profile guided our consistency in column naming and definitions. Medical Imaging CDM (MI-CDM), constructed using the entity-attribute-value (EAV) model, facilitates scalable and efficient MI data management. For lung cancer patients diagnosed between 2010 and 2017, we introduced four new tables—IMAGING_STUDY, IMAGING_SERIES, IMAGING_ANNOTATION, and FILEPATH—to standardize various imaging-related data and link to clinical data.

Results:

This framework underscores the effectiveness of MI-CDM in enhancing our understanding of lung cancer diagnostics and treatment strategies. The implementation of the MI-CDM tables enabled the structured organization of a comprehensive dataset, including 275,446 IMAGING_STUDY, 5,346,571 IMAGING_SERIES, and 34,449 IMAGING_ANNOTATION records, illustrating the extensive scope and depth of the approach. A scenario-based analysis using actual data from patients with lung cancer underscored the feasibility of our approach. A data quality check applying 44 specific rules confirmed the high integrity of the constructed dataset, with all checks successfully passed, underscoring the reliability of our findings.

Conclusions:

These findings indicate that MI-CDM can improve the integration and analysis of medical imaging and clinical data. By addressing the challenges in data standardization and management, our approach contributes toward enhancing diagnostics and treatment strategies. Future research should expand the application of MI-CDM to diverse disease populations and explore its wide-ranging utility for medical conditions.


 Citation

Please cite as:

Yoo S, Ji H, Kim S, Sunwoo L, Jang S, Lee HY

Integrating Clinical Data and Medical Imaging in Lung Cancer: Feasibility Study Using the Observational Medical Outcomes Partnership Common Data Model Extension

JMIR Med Inform 2024;12:e59187

DOI: 10.2196/59187

PMID: 38996330

PMCID: 11282389

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.